Valion Bio (VBIO) Depreciation & Amortization (CF) (2021 - 2026)
Valion Bio (VBIO) posted quarterly Depreciation & Amortization (CF) of $3000.0 for Q4 2025, up 200.0% quarter-over-quarter from $1000.0 in Q2 2025.
Valion Bio (VBIO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Valion Bio's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $3000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $3000.0; the TTM figure through Dec 2025 stood at $5000.0 (up 66.67% YoY), while the FY2025 annual figure was $5000.0, up 66.67% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $3000.0, up from $1000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $3000.0 in Q3 2022, with the low at $1000.0 in Q3 2023.
- The 5-year median for Depreciation & Amortization (CF) is $2000.0 (2021), against an average of $1888.9.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 50.0% in 2022, then sank 66.67% in 2023.
- Valion Bio's Depreciation & Amortization (CF) stood at $2000.0 in 2021, then jumped by 50.0% to $3000.0 in 2022, then plunged by 33.33% to $2000.0 in 2023, then slumped by 50.0% to $1000.0 in 2024, then surged by 200.0% to $3000.0 in 2025.
- Business Quant data shows VBIO's Depreciation & Amortization (CF) at $3000.0 in Q4 2025, $1000.0 in Q2 2025, and $1000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358,000.00 |
| Jun 30, 2026 | 358,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 3,000.00 |